MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.xkme.2026.101496

Медицинская библиотека · Kidney medicine · 2026

Effects of Lanthanum Carbonate on Whole-Body Phosphorus and Calcium Balance in Adults With Chronic Kidney Disease and Normophosphatemia.

Jovanovich Anna, Chonchol Michel, Struemph Taylor, Marden Tyson J, Oh Ester, You Zhiying, Levi Moshe, Schwartz Gregory G, Nowak Kristen L, Hill Gallant Kathleen M

СтатьяПеревод пока не подготовлен

Аннотация

RATIONALE &

OBJECTIVE

Greater serum phosphorus is associated with cardiovascular disease in those with chronic kidney disease (CKD). However, the utility of phosphorus lowering in nondialysis-requiring CKD is not clear. The effects of noncalcium-based phosphate binders on phosphorus and calcium balance in nondialysis-requiring CKD are unknown. Our objective was to determine phosphorus and calcium balance in normophosphatemic adults with CKD 3b-4 after 12 weeks of treatment with lanthanum carbonate or placebo.

STUDY

DESIGN

Prospective, randomized, controlled, double-blind clinical trial.

SETTING &

PARTICIPANTS

A subset of 15 adults with CKD 3b-4 and serum phosphorus levels within normal limits who participated in a 12-week parallel-arm, randomized controlled trial of lanthanum carbonate compared with placebo on vascular function participated in this study extension.

INTERVENTION: At the end of 12 weeks, the subset of participants consumed a controlled diet (1,000 mg/day phosphorus and 800 mg/day calcium) for 9 days and continued their randomly assigned study drug (N = 7 lanthanum carbonate, N = 8 placebo). Fasting morning blood samples and all stool and urine were collected during a 48-hour inpatient clinical research center stay at the end of the 9-day controlled diet period.

OUTCOMES: Phosphorus and calcium balance (mg/d) were determined by values averaged over the 48 hours inpatient clinical research center admission.

RESULTS

Mean age was 65 ± 8 (SD) years, and mean estimated glomerular filtration rate was 38 ± 14 (SD) mL/min/1.73m2. Whole-body phosphorus balance was lower with lanthanum carbonate compared with placebo (-131 ± 163 [SEM] vs 320 ± 141 mg/d, P = 0.05), as was calcium balance (-46 ± 115 [SEM] vs 410 ± 100 mg/d, P = 0.01), corresponding to lower intestinal absorption supported by the fecal calcium and phosphorus and net absorption results. Neither 24-hour urine calcium nor phosphorus output was significantly different between lanthanum carbonate and placebo, but 24-hour urine phosphorus output differed between lanthanum carbonate and placebo but was not significant (388 ± 60 vs 513 ± 56 mg/d, p=0.15).

LIMITATIONS: Small sample size.

CONCLUSIONS

Twelve weeks of treatment with the noncalcium-based phosphate binder, lanthanum carbonate, may reduce whole-body phosphorus balance as well as calcium balance among adults with stage 3b-4 CKD and normophosphatemia. Whether reduced phosphorus balance or calcium balance with lanthanum carbonate is associated with beneficial clinical outcomes in CKD warrants further investigation.

Для цитирования: Jovanovich Anna, Chonchol Michel, Struemph Taylor, Marden Tyson J, Oh Ester, You Zhiying, Levi Moshe, Schwartz Gregory G, Nowak Kristen L, Hill Gallant Kathleen M. Effects of Lanthanum Carbonate on Whole-Body Phosphorus and Calcium Balance in Adults With Chronic Kidney Disease and Normophosphatemia.. Kidney medicine. 2026. DOI: 10.1016/j.xkme.2026.101496.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.